Lymphoproliferative Disorders
52
15
20
12
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.7%
4 terminated out of 52 trials
75.0%
-11.5% vs benchmark
4%
2 trials in Phase 3/4
42%
5 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (52)
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Clonal Hematopoiesis of Immunological Significance
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Feasibility of a Multi-omics Platform for Hematological Malignancies
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Virtual Rehabilitation for Cancer Survivors
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Pathogenesis of Hematologic Malignancies
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers